Ki-67 Index as a Biomarker of Response to Cytotoxic Chemotherapy Abstract #845

Introduction: Chemotherapy (CT) is widely used for neuroendocrine tumors (NET) but there are no validated biomarkers to predict response. The Ki-67 proliferation index has been proposed as a means of selecting patients for CT but robust data are lacking.
Aim(s): We investigated the relationship between response and Ki-67, and sought to define a cut-off for patient stratification.
Materials and methods: We reviewed data from 152 patients treated with 5-fluorouracil, cisplatin and streptozocin (FCiSt). Tumors were graded according to Ki-67 index: low ≤5%, intermediate 5-20% and high >20%. Radiological response was assessed by RECIST and survival calculated from start of chemotherapy to death. To explore the utility of Ki-67 as a marker of response, we calculated the likelihood ratio and performed receiver operating characteristic (ROC) analysis.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Alexa Childs
Keywords: chemotherapy, Ki-67

To read results and conclusion, please login ...

Further abstracts you may be interested in

#920 High Grade (G3) Neuroendocrine Neoplasms Should Be Further Classified According to Morphological Differentiation
Introduction: Neuroendocrine neoplasms (NENs) with a Ki-67 >20% (Grade 3) are classified together as Neuroendocrine Carcinomas (NEC), and are usually considered as poorly differentiated. However Grade (G)3 NENs may be heterogeneous, with some demonstrating a well-differentiated cell morphology.
Conference: 11th Annual ENETS Conference (2014)
Category: ...none of the below
Presenting Author: Dr Dalvinder Mandair
Keywords: Ki-67, g3 NENs
#489 Goblet Cell Appendiceal Neuroendocrine Tumors: Diagnosis, Recurrence Rates, Treatment and Survival. A Series of 37 Patients
Introduction: Goblet cell appendiceal neuroendocrine tumors (GCA-NETs) share histologic features of both adenocarcinomas and NETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Christos Toumpanakis
#2189 Perioperative Chemotherapy in Resectable Neuroendocrine Carcinomas of the Digestive Tract
Introduction: Neuroendocrine carcinomas (NEC), of the digestive tract are rare and aggressive tumours. In localised disease, the treatment is surgery, followed by administration of adjuvant chemotherapy combining etoposide and platinum salts, justified by the high risk of secondary metastasis. No clinical study has proven the benefit of chemotherapy, and recommendations are based on expert consensus.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Anna Pellat
#1008 STZ-Based Chemotherapy is Associated with Durable Response Rate in Pancreatic NET as 1st or 2nd Line Treatment
Introduction: The role of chemotherapy for pancreatic neuroendocrine tumors (pNETs) is controversially discussed. Objective response rates (RR) with streptozocin (STZ)-based chemotherapy are variable. Novel targeted drugs have recently been approved.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Lisa-Marie Dilz
#1373 Comparison of Somatostatin Analogue (SA) and Chemotherapy (CT) in Neuroendocrine Tumors (NET) Patients with Ki-67 ≤20%
Introduction: SA and CT are the most important treatment options for grade (G) 1 and G2 NET patients.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: M.D. Ersin Özaslan